FINANCINGS
Abeona Therapeutics Inc. priced an underwritten public offering for gross proceeds of approximately $42 million.
Blackthorn Therapeutics Inc. has closed a $40 million series A round.
Bonesupport AB raised $37 million from a combination of equity and debt finance.
Castle Creek Pharmaceuticals Inc. has completed a $48 million capital raise.
Collegium Pharmaceutical Inc. priced a public offering for gross proceeds of $80 million, which will rise to $92 million if the underwriters' option is exercised in full.
Genomics Medicine Ireland (GMI) Ltd. raised $40 million from a series A financing.
Myovant Sciences Ltd. raised $217.5 million from its IPO.
Oasmia Pharmaceutical AB completed a private placement of 8.75 million new shares, providing the company with $7.8 million.
Pluristem Therapeutics Inc. signed a term sheet for an investment of about $30 million from China-based Innovative Medical Management Co. Ltd.
Puma Biotechnology Inc. closed its public offering with net proceeds totaling about $162 million.
Ra Pharmaceuticals Inc. priced its IPO of 7.04 million shares of common stock at $13 each. The company has granted the underwriters a 30-day option to purchase up to 1.05 million additional shares of common stock at the IPO price.
Siga Technologies Inc. has begun a rights offering for gross proceeds of about $35 million.
Sunesis Pharmaceuticals Inc. closed underwritten offerings for net proceeds of about $25.9 million.
Unity Biotechnology Inc. generated $116 million from its series B round of financing.
DEALS
Active Biotech AB and Neotx Therapeutics Ltd. signed a licensing deal for Anyara (naptomumab estafenatox), Active's immunotherapy compound.
Allergan plc exercised its option to acquire Rhythm Holding Co. LLC subsidiary Motus Therapeutics Inc. for $200 million.
Biocardia Inc. closed its merger with Tiger X Medical Inc.
Braeburn Pharmaceuticals Inc. and Camurus AB are expanding their collaboration and license agreement to include a new combination product for pain and nausea.
Dong-A ST Co. Ltd. and Beactica AB signed a research and drug discovery collaboration and licensing agreement to jointly develop cancer drugs against certain disease-related oncology targets.
Evotec AG is acquiring Cyprotex plc in an all-cash deal valued at $67.5 million.
Sunovion Pharmaceuticals Inc. completed its acquisition of Cynapsus Therapeutics Inc. for $624 million in cash.
. . . AND MORE
Apricus Biosciences Inc. announced a reverse stock split of its shares of common stock at a ratio of 1-for-10 in an effort to regain compliance with Nasdaq listing rules.
Atyr Pharma Inc. said its Resolaris was granted fast track designation by the FDA for the treatment of facioscapulohumeral muscular dystrophy.
Cel-Sci Corp. received a partial clinical hold letter from the FDA regarding its phase III study of Multikine (leukocyte interleukin, injection) as a neoadjuvant treatment in squamous cell carcinoma of the head and neck.
Dipexium Pharmaceuticals Inc. reported that a pair of identical phase III trials of Locilex (pexiganan cream 0.8 percent) in mild infections of diabetic foot ulcers missed the primary endpoint of superiority vs. vehicle plus standardized wound care.
Heat Biologics Inc. formed a wholly owned subsidiary, Zolovax Inc., to develop gp96-based vaccines targeting Zika, HIV, West Nile, dengue and yellow fever.
Merck & Co. Inc. received FDA approval for Zinplava (bezlotoxumab), a monoclonal antitoxin antibody targeting Clostridium difficile infection in adults at high risk for recurrence of the infection who are also on antibacterial therapy.
Shire plc said Health Canada approved Vyvanse (lisdexamfetamine dimesylate) for moderate to severe binge eating disorder in adults.